Cargando…

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) is a World Health Organization’s high priority pathogen organism, with an estimated > 100,000 deaths worldwide in 2019. Thus, there is an unmet medical need for novel and resistance-breaking anti-infectives. The natural product Co-rallopyronin A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rox, Katharina, Becker, Tim, Schiefer, Andrea, Grosse, Miriam, Ehrens, Alexandra, Jansen, Rolf, Aden, Tilman, Kehraus, Stefan, König, Gabriele M., Krome, Anna K., Hübner, Marc P., Wagner, Karl G., Stadler, Marc, Pfarr, Kenneth, Hoerauf, Achim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860980/ https://www.ncbi.nlm.nih.gov/pubmed/36678760 http://dx.doi.org/10.3390/pharmaceutics15010131

Ejemplares similares

In Vitro–In Vivo Relationship in Mini-Scale—Enabling Formulations of Corallopyronin A
por: Becker, Tim, et al.
Publicado: (2022)

Corallopyronin A for short-course anti-wolbachial, macrofilaricidal treatment of filarial infections
por: Schiefer, Andrea, et al.
Publicado: (2020)

Solubility and Stability Enhanced Oral Formulations for the Anti-Infective Corallopyronin A
por: Krome, Anna K., et al.
Publicado: (2020)

The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus
por: Balansky, Jan, et al.
Publicado: (2022)

Complete Genome Sequence of the Corallopyronin A-Producing Myxobacterium Corallococcus coralloides B035
por: Bouhired, Sarah, et al.
Publicado: (2019)

Potent In Vitro and Ex Vivo Anti-Gonococcal Activity of the RpoB Inhibitor Corallopyronin A
por: Edwards, Jennifer L., et al.
Publicado: (2022)

Elaborations on Corallopyronin A as a Novel Treatment Strategy Against Genital Chlamydial Infections
por: Loeper, Nathalie, et al.
Publicado: (2019)

Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis
por: Ehrens, Alexandra, et al.
Publicado: (2022)

Eosinophils in filarial infections: Inducers of protection or pathology?
por: Ehrens, Alexandra, et al.
Publicado: (2022)

NOD2 dependent neutrophil recruitment is required for early protective immune responses against infectious Litomosoides sigmodontis L3 larvae
por: Ajendra, Jesuthas, et al.
Publicado: (2016)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration
por: Pfarr, Kenneth M., et al.
Publicado: (2023)

The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use
por: Pfarr, Kenneth M., et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus
por: Kebriaei, Razieh, et al.
Publicado: (2017)

Susceptibility to L. sigmodontis infection is highest in animals lacking IL-4R/IL-5 compared to single knockouts of IL-4R, IL-5 or eosinophils
por: Frohberger, Stefan J., et al.
Publicado: (2019)

Quinolone-fused cyclic sulfonamide as a novel benign antifilarial agent
por: Mukherjee, Suprabhat, et al.
Publicado: (2018)

The Annotated Genome of Wolbachia from the Filarial Nematode Brugia malayi: What It Means for Progress in Antifilarial Medicine
por: Pfarr, Kenneth, et al.
Publicado: (2005)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
por: Zeitlinger, Markus, et al.
Publicado: (2023)

Helminths and their implication in sepsis – a new branch of their immunomodulatory behaviour?
por: Hübner, Marc P, et al.
Publicado: (2013)

In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae
por: Hübner, Marc P., et al.
Publicado: (2019)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

AmiD Is a Novel Peptidoglycan Amidase in Wolbachia Endosymbionts of Drosophila melanogaster
por: Wilmes, Miriam, et al.
Publicado: (2017)

S100A8/S100A9 deficiency increases neutrophil activation and protective immune responses against invading infective L3 larvae of the filarial nematode Litomosoides sigmodontis
por: Frohberger, Stefan J., et al.
Publicado: (2020)

ILC2s Control Microfilaremia During Litomosoides sigmodontis Infection in Rag2(-/-) Mice
por: Reichwald, Julia J., et al.
Publicado: (2022)

The efficacy of the benzimidazoles oxfendazole and flubendazole against Litomosoides sigmodontis is dependent on the adaptive and innate immune system
por: Risch, Frederic, et al.
Publicado: (2023)

Human filariasis—contributions of the Litomosoides sigmodontis and Acanthocheilonema viteae animal model
por: Risch, Frederic, et al.
Publicado: (2021)

Macrofilaricidal efficacy of single and repeated oral and subcutaneous doses of flubendazole in Litomosoides sigmodontis infected jirds
por: Hübner, Marc P., et al.
Publicado: (2019)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches
por: Khalid, Kashaf, et al.
Publicado: (2023)

1535. Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of Cefepime (CPM) in Obese and Non-Obese Patients
por: Morrisette, Taylor, et al.
Publicado: (2019)

Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin Against Streptococcus suis in Piglets
por: Wang, Rui-Ling, et al.
Publicado: (2022)

Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the Litomosoides sigmodontis mouse model
por: Specht, Sabine, et al.
Publicado: (2018)

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

Lack of Clinically Relevant Effect of Bictegravir (BIC, B) on Metformin (MET) Pharmacokinetics (PK) and Pharmacodynamics (PD)
por: Custodio, Joseph, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_peikc7avatr8u7jqtvvhpgrcbd